Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS On May 6, 2019, the Company granted options to purchase an aggregate of 255,000 shares of the Company’s common stock to the non-executive members of its Board of Directors with an exercise price of $2.05, with a term of ten years, vesting on the on the one year anniversary of the date of issuance. On May 6, 2019, the Company granted options to purchase an aggregate of 346,021 shares of the Company’s common stock to employees with an exercise price of $2.05, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months. Additionally, the Company granted options to purchase 230,679 shares of the Company’s common stock to employees with an exercise price of $2.56, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months.

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2019

NOTE 10 – SUBSEQUENT EVENTS

On May 6, 2019, the Company granted options to purchase an aggregate of 255,000 shares of the Company’s common stock to the non-executive members of its Board of Directors with an exercise price of $2.05, with a term of ten years, vesting on the on the one year anniversary of the date of issuance.

On May 6, 2019, the Company granted options to purchase an aggregate of 346,021 shares of the Company’s common stock to employees with an exercise price of $2.05, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months. Additionally, the Company granted options to purchase 230,679 shares of the Company’s common stock to employees with an exercise price of $2.56, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months.